Frontiers in Oncology · 2022 · 10 citations · 12 references
MedicineOncologyMolecular OncologyPrecision MedicinePrecision OncologyCancer Precision MedicineCirculating Tumor Dna AnalysisColorectal CancerLiquid BiopsyMalignant NeoplasmsNext-generation Sequencing In OncologyCetuximab TherapyCirculating Tumor Dna SequencingCirculating Tumor Dna TestingEgfr InhibitionLiquid Biopsy Mutation AnalysisNext-generation Sequencing AssaysOncogenic Ras MutationsReal-time Polymerase Chain Reaction (Pcr)
Background Rechallenge with EGFR inhibitors represents a promising strategy for patients with RAS wild type (WT) colorectal cancer (CRC) but definitive selection criteria are lacking. Recently, the RAS WT status on circulating tumor DNA (ct-DNA) emerged as a potential watershed for this strategy. Our study explored the liquid biopsy-driven cetuximab rechallenge in a RAS and BRAF WT selected population. Methods CRC patients with RAS and BRAF WT both on tumor tissue and on ct-DNA at baseline receiving rechallenge with cetuximab were eligible for our analysis. Ct-DNA was analyzed for RAS-BRAF mutations with pyro-sequencing and nucleotide sequencing assays. Real-time PCR and droplet digital PCR were performed to confirm the RAS-BRAF mutational status. Results A total of 26 patients were included in our analysis. In the global population, RR was 25.0%, median overall survival (mOS) was 5.0 months, and median progression-free survival (mPFS) was 3.5 months. Previous response to anti-EGFR was associated with improved mPFS (5.0 vs. 2.0 months, HR: 0.26, p = 0.048); anti-EGFR free interval > 14 months and anti-EGFR free interval > 16 months were associated with improved mPFS (respectively 7.0 vs. 3.0 months, HR: 0.27, p = 0.013 and not reached vs. 3.0 months, HR: 0.20, p = 0.002) and with improved mOS (respectively 13.0 vs. 5.0 months, HR: 0.27, p = 0.013 and 13.0 vs. 5.0 months, HR: 0.20, p = 0.002). Previous lines >2 were correlated with improved mPFS (4.0 vs. 1.0 month, HR: 0.05, p = 0.041) and with improved mOS (7.0 vs. 1.0 month, HR: 0.045, p = 0.034). In a multiple logistic regression model, only the anti-EGFR free interval was confirmed to be a significant predictor for mOS and mPFS. Conclusions Liquid biopsy-driven cetuximab rechallenge was confirmed to be effective. The clinical outcome was consistent with available results from phase II studies. In addition to the molecular selection through the analysis of ct-DNA for RAS, the long anti-EGFR free interval is confirmed as a prospective selection criterion for this therapeutic option.
12
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A. Díaz, Richard T. Williams, Jian Wu et al. · Nature · 2012 · 1.7K citations · Full text
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone et al. · New England Journal of Medicine · 2015 · 1.4K citations · Full text
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna, Benedetta Mussolin, Michela Buscarino et al. · Nature Medicine · 2015 · 1.1K citations · Full text
Medicine, Cancer Biology, Oncology +16
Chiara Cremolini, Daniele Rossini, Emanuela Dell’Aquila et al. · JAMA Oncology · 2018 · 420 citations · Full text
Medicine, Oncology, Pharmacology +17